• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
  1. Is the full text of the article in English?
    Yes......................................................................Proceed to #2
    No...................................................................Code X1. STOP
  2. Is the article a controlled clinical trial or a systematic review/meta-analysis of controlled trials comparing the effects of supplemental/non-dietary carotenoids, antioxidants, or omega-3 fatty acids (alone or in combination) with usual care or placebo?
    Yes......................................................................Proceed to #3
    No...............................................................Code X2. Go to #6
  3. Does the population include adults with age-related macular degeneration?
    Yes.......................................................................Proceed to #4
    No........................................................................Proceed to #5
  4. Does the study report outcomes that include vision loss, quality of life, functional status, or adverse effects of treatment?
    Yes....................................................................Code I4. STOP
    No...............................................................Code X4. Go to #6
  5. Does the study report the adverse effects of treatment in a population of ≥100 adults without age-related macular degeneration who were observed for >24 weeks?
    Yes.................................................................... Code I5. STOP
    No.......................................................Code X5. Proceed to #6
  6. Is the article potentially useful for background, discussion, or reference-mining?
    Yes............................................................ Add Code B. STOP
    No................................................................................... STOP
PICOTS
Patients:KQ1:Adults with age-related macular degeneration
KQ2:Adults, exclude patients with severe chronic illnesses such as end-stage liver disease, ESRD, severe COPD, metastatic cancer, ALS, severe heart failure
Interventions:Carotenoids – zeaxanthin, lutein, beta carotene
Antioxidants – zinc, vitamin e, vitamin c
Omega-3 fatty acids – alpha linolenic acid (C18:3n-3), docosahexaenoic acid (DHA; C22:6n-3), eicosapentaenoic acid (EPA; C20:5n-3)
Comparators: Placebo, usual care (usual diet)
Outcomes: Vision loss
Visual impairment in the best eye defined as: ≤ 20/60 by Snellen acuity; or ≤ 6/18 metric acuity; or doubling of the visual angle (e.g. 20/50 to 20/100); or ≥ three lines of loss; or ≥ 15 letters lost; or progression to advanced disease (either geographic atrophy or wet macular degeneration); quality of life; functional status.

From: APPENDIX B, INCLUSION/EXCLUSION CRITERIA

Cover of Nutritional Supplements for Age-Related Macular Degeneration: A Systematic Review
Nutritional Supplements for Age-Related Macular Degeneration: A Systematic Review [Internet].
Kansagara D, Gleitsmann K, Gillingham M, et al.
Washington (DC): Department of Veterans Affairs (US); 2012 Jan.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.